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Autosomal recessive inheritance. Male to female ratio 
1.7 : 1. 
Clinics 
Note 
Bone marrow failure syndrome with exocrine 
pancreatic dysfunction and growth retardation, many 
phenotypic features often present at birth. 
Phenotype and clinics 
Intermittent neutropenia is the most common 
haematological finding (85-100%); in addition aplastic 
anemia (80%), increased hemoglobin F levels (80%), 
thrombocytopenia (25-85%) and impaired neutrophil 
chemotaxis, B- and T-cell defects can be found. 
Fluctuating or persistent exocrine pancreatic 
dysfunction (with low serum amylase in 50-75%, low 
serum trypsinogen in 70-98% and abnormal pancreatic 
stimulation test in nearly 100%). 
Growth retardation (shortness 60%, weight 50%, 
microcephalus <50%). 
Other manifestations include delayed puberty, rib and
thoracic bone abnormalities 30-50%, metaphyseal 
dysostosis 50-75%, dental dyplasia, hepatomegaly 10-
60%, elevated liver transaminases 50-75%, Ichtyosis 
severe and recurrent viral, bacterial and fungal 
infections 50-75% and developmental delay. 
Neoplastic risk 
The risk for AML in SDS is estimated to be 15-25%. 
MDS has been found in small cohorts of SDS  
patients in 10-44%. The predilection to malignant 
myeloid transformation is higher in SDS patients with 
evolving pancytopenia and can already occur during 
infancy. 
Treatment 
Pancreatic insufficiency can be treated with pancreatic 
enzyme replacement. Periodic monitoring for the 
occurrence of haematological manifestations and 
supportive care for pancytopenia are mandatory. GCSF 
is used for individuals with severe neutropenia and 
recurrent infections. Because of the possible underlying 
liver abnormalities androgen-therapy is not 
recommended. Bone marrow transplantation from a 
family- or alternative donor is the only curative opti n 
for severe bone marrow failure and is recommended in 
SDS patients with severe pancytopenia and evolving 
haematological malignancies. 
Prognosis 
Morbidity and mortality in infancy is related to 
infections, maldigestion and malabsorbtion and 
thoracic dystrophy. Pancreatic insufficiency that cn be 
severe in infancy improves with increasing age in up to 
50% of patients. In older children and adults, the main 
cause for morbidity and mortality are haematological. 
MDS and AML in patients with SDS has a poor 
prognosis, with a survival rate of < 20%. 
Cytogenetics 
Inborn conditions 
Rare reports of increase in spontaneous chromosomal 
breakage. 
Cancer cytogenetics 
Clonal aberrations are common and frequently involve 
chromosome 7, typically in form of i(7)(q10). 
Del(20q) represents the second most common  
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aberration, often occurring as secondary event to 
i(7)(q10). 
Clonal aberrations need not indicate imminent 
transformation to MDS/AML and can be transient in 
nature. 
Over 60% of transformed cases will have an abnormal 




Additional reported findings. 
Over-expression of p53 protein. 
Abnormal telomeric shortening. 
Increased apoptosis mediated through the Fas pathway. 





Description: 5 exons spanning 7.9kb. 
Protein 
Description: Predicted protein is 28.8 kD. 
Function: Member of highly conserved protein family 
of unknown function. 
Mutations 
Germinal: Various mutations have been described, 
including mutations resulting in stop codons and simple 
amino acid substitution. 
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